Clinical Division of Oncology, Comprehensive Cancer Center, Medical University Vienna-General Hospital, Vienna, Austria; Central European Cooperative Oncology Group.
Medical Oncology Department, Institute of Oncology, Cluj-Napoca, Romania.
Ann Oncol. 2012 May;23(5):1223-1229. doi: 10.1093/annonc/mdr381. Epub 2011 Sep 22.
The current third consensus on the systemic treatment of non-small-cell lung cancer (NSCLC) builds upon and updates similar publications on the subject by the Central European Cooperative Oncology Group (CECOG), which has published such consensus statements in the years 2002 and 2005 (Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer--update 2004. Lung Cancer 2005; 50: 129-137). The principle of all CECOG consensus is such that evidence-based recommendations for state-of-the-art treatment are given upon which all participants and authors of the manuscript have to agree (Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771-1785). This is of particular importance in diseases in which treatment options depend on very particular clinical and biologic variables (Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer--update 2004. Lung Cancer 2005; 50: 129-137; Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771-1785). Since the publication of the last CECOG consensus on the medical treatment of NSCLC, a series of diagnostic tools for the characterization of biomarkers for personalized therapy for NSCLC as well as therapeutic options including adjuvant treatment, targeted therapy, and maintenance treatment have emerged and strongly influenced the field. Thus, the present third consensus was generated that not only readdresses previous disease-related issues but also expands toward recent developments in the management of NSCLC. It is the aim of the present consensus to summarize minimal quality-oriented requirements for individual patients with NSCLC in its various stages based upon levels of evidence in the light of a rapidly expanding array of individual therapeutic options.
目前，非小细胞肺癌（NSCLC）系统治疗的第三次共识是基于中欧合作肿瘤组（CECOG）在该主题上发表的类似出版物，并在 2002 年和 2005 年发布了此类共识声明（Zielinski CC、Beinert T、Crawford J 等人。非小细胞肺癌的医学治疗共识-2004 年更新。肺癌 2005；50:129-137）。所有 CECOG 共识的原则是，根据最新的治疗方法，给出基于证据的建议，所有参与者和手稿作者都必须同意（Beslija S、Bonneterre J、Burstein HJ 等人。转移性乳腺癌的第三次医学治疗共识。安· Oncol 2009；20（11）：1771-1785）。在治疗选择取决于非常特殊的临床和生物学变量的疾病中，这一点尤为重要（Zielinski CC、Beinert T、Crawford J 等人。非小细胞肺癌的医学治疗共识-2004 年更新。肺癌 2005；50:129-137；Beslija S、Bonneterre J、Burstein HJ 等人。转移性乳腺癌的第三次医学治疗共识。安· Oncol 2009；20（11）：1771-1785）。自 CECOG 上次发布关于 NSCLC 医学治疗的共识以来，一系列用于 NSCLC 个体化治疗生物标志物特征描述的诊断工具以及治疗选择，包括辅助治疗、靶向治疗和维持治疗，已经出现并对该领域产生了重大影响。因此，目前的第三次共识不仅重新考虑了以前与疾病相关的问题，而且还扩展到了 NSCLC 管理的最新发展。本共识的目的是根据证据水平，根据不断扩展的个体化治疗选择，总结不同阶段的 NSCLC 患者的最低质量导向要求。
